Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster And Better Symptom Control Than Concerta(R)1 In Early Part Of ADHD Patients' Day

A head-to-head study, published in the June Journal of Child and Adolescent Psychopharmacology, confirms that Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules offer greater improvements in managing symptoms of Attention Deficit/Hyperactivity Disorder compared with Concerta(R) (d,l- methylphenidate HCl) extended-release tablets at two hours post-dose, the primary study endpoint.

Protein On 'Speed' Linked To ADHD

A genetic change in the dopamine transporter - one of the brain's dopamine-handling proteins - makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience. The altered function of the transporter gene variant, discovered in two brothers with attention deficit hyperactivity disorder (ADHD), supports a role for dopamine signaling in the disease.

Celebrity Designer And ADHD Spokesperson Ty Pennington Partners With Shire To Announce The Launch Of VYVANSEв„ў For Adult ADHD Treatment

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has launched VYVANSEв„ў (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths.

Shire Re-Launches ADHDSupport.com, A Virtual Road Map Providing Information, Tools And Practical Tips About Attention Deficit Hyperactivity Disorder

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today the re-launch of its educational Web site, ADHDSupport.com, designed to provide families, caregivers, educators and patients with tools and resources about Attention Deficit Hyperactivity Disorder (ADHD). The newly enhanced ADHDSupport.

ADHD - The Essential Guide, New Bood

Does your child have frequent temper tantrums? Are they always fidgeting, running around screaming or falling over? Perhaps you teach a child like that. If so, the chances are there's nothing to worry about and they are just being boisterous. But for five to ten percent of children it isn't that simple. These characteristics can be some of the symptoms of Attention Deficit Hyperactive Disorder (ADHD).

Neuroscientists Work Their Magic

Two neuroscientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center are turning magic tricks into science. Stephen Macknik, Ph.D., director of the Laboratory of Behavioral Neurophysiology; and Susana Martinez-Conde, Ph.D., director of the Laboratory of Visual Neuroscience; are working with world-famous magicians to discover the brain's mechanisms underlying attention and awareness.

CHADD And AACAP Applaud Michael Phelps For Addressing Stigma Of ADHD

Children and Adults with Attention-Deficit Hyperactivity Disorder (CHADD) and the American Academy of Child and Adolescent Psychiatry (AACAP) applaud Olympic gold-medalist Michael Phelps and his mother, Mrs. Deborah Phelps for educating the public about succeeding with attention-deficit/hyperactivity disorder (AD/HD). "Congratulations to Michael Phelps for winning eight Olympic gold medals. I applaud him and his mother for speaking about AD/HD. Mr.

Hayes Evaluates Test And Treatment Options For Attention-Deficit Hyperactivity Disorder

Hayes, Inc., an industry leader in providing independent, unbiased analyses of healthcare technologies, today announced that it has completed an exhaustive study of a wide range of medications to treat attention-deficit hyperactivity disorder (ADHD). The study was undertaken in response to significant customer interest in gaining a better understanding of those treatments that really work to relieve symptoms in ADHD sufferers.

CHADD And AACAP Applaud Michael Phelps For Addressing Stigma Of AD/HD

"Congratulations to Michael Phelps for winning eight Olympic gold medals. I applaud him and his mother for speaking about AD/HD. Mr. Phelps shows that it's possible to go beyond coping with AD/HD and truly achieve. His candor addresses stigma and, hopefully, will inspire others to seek help," said AACAP President Robert Hendren, D.O.

US Pharmacies Now Supply ADHD Medication VYVANSE In 6 Dosage Strengths

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The expanded VYVANSE dosing options will allow physicians to individualize treatment for each patient.

VYVANSE(R) Now Available In U.S. Pharmacies Nationwide In Six Dosage Strengths - ADHD

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The expanded VYVANSE dosing options will allow physicians to individualize treatment for each patient.

Attention Deficit/Hyperactivity Disorder (AD/HD) Community Comes Together For First Ever Virtual Conference

Twenty-two of the most celebrated doctors, therapists, and coaches in the field of Attention Deficit/Hyperactivity Disorder (AD/HD) are coming together for the first time in a virtual setting. From September 22-24, 2008, people affected by AD/HD, including parents, service professionals, and AD/HD adults, will hear live presentations from experts including: - Dr. Edward Hallowell, author of "Driven to Distraction" - Dr.

Sciele Pharma And Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results Of Clonicel For ADHD

Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel^ for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) showed statistically significant improvement over placebo.

Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results For Clonicel To Treat ADHD

A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.

Critical Early Step Of Memory Formation Discovered By Johns Hopkins Neuroscientists

Researchers at the Johns Hopkins University School of Medicine report in Neuron how nerve cells in the brain ensure that Arc, a protein critical for memory formation, is made instantly after nerve stimulation. Paradoxically, its manufacture involves two other proteins - including one linked to mental retardation - that typically prevent proteins from being made.

Majority Of Teachers 'Have Difficulty Understanding And Managing ADHD', Royal College Of Psychiatrists

Two thirds of primary school teachers struggle to understand and manage attention deficit hyperactivity disorder (ADHD) behaviour because of a lack of training, new research shows. The study, presented at the annual conference of Royal College of Psychiatrists' Faculty of Child and Adolescent Psychiatry, surveyed teachers from six primary schools in Plymouth.

More Attention Needed On ADHD In School - Over 80% Of The Teachers Surveyed Want More ADHD Training, UK

A new survey has revealed that over half of UK teachers have not had any training about Attention Deficit Hyperactivity disorder (ADHD). [1] With millions of UK children back to school this month, this finding paints a distressing picture for the estimated 5% of school age children in the UK who have ADHD.[2] These results are also particularly concerning as teachers are the most commonly used source of help in the UK for 70% of parents of children with ADHD.

European Project To Study Relationship Between ADHD And Substance Abuse

To determine the relationship between Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD) and the development SUD in patients with and without ADHD. These are the main goals of the European collaborative initiative that was launched today. In the coming years 14 addiction treatment centers in 10 EU countries will include over 6.000 patients with SUD.

National Survey Reveals Impact Of ADHD In Adults

Adults diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) say that having ADHD significantly impacts their ability to focus at work, as well as their responsibilities at home and their relationships. These findings were according to a national survey including more than 1,000 adults across the United States diagnosed with the condition.

NICE Guidelines Are Set To Improve Care And Management Of Children, Young People And Adults With ADHD, UK

The National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Mental Health have today (24 September 2008) published a guideline on the diagnosis and management of attention deficit hyperactivity disorder (ADHD) in children, young people and adults. ADHD is a common behavioural disorder in children and young people estimated to affect up to 3% of school-age children and young people in the UK, and about 2% of adults worldwide.

Autism, Learning Disabilities And ADHD Experts Convene At The Help Group Summit

On Friday, September 26 and Saturday, September 27, 2008 at The Skirball Cultural Center in Los Angeles, The Help Group will host its Summit 2008, Advances and Best Practices in Autism, Learning Disabilities and ADHD.

Richard D. Todd, Ph.D., M.D., Receives AACAP Elaine Schlosser Lewis Award For Research On Attention-Deficit Disorder

The late Richard D. Todd, Ph.D., M.D., is the recipient of the 2008 American Academy of Child and Adolescent Psychiatry Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder. His paper, "Predictors of Stability of Attention-Deficit/Hyperactivity Disorder Subtypes From Childhood to Young Adulthood," was selected as the best paper on ADHD published in the Journal of the American Academy of Child and Adolescent Psychiatry during the past year. Dr.

Study Finds People With Fragile X, Carriers Likely To Have Additional Conditions

People with fragile X syndrome, as well as those who carry the gene, are likely to have additional conditions that include attention problems and anxiety, according to a study by researchers at RTI International. The study, published in the Aug. 15 issue of American Journal of Medical Genetics, surveyed more than 1,000 parents of children who either had fragile X syndrome, the most common inherited cause of intellectual disability, or were a carrier of the disease.

WPIC Mental Health And Wellness Lecture Series To Begin October 1

The University of Pittsburgh's Clinical and Translational Science Institute Community PARTners Program and the Research Network Development Core at Western Psychiatric Institute and Clinic of UPMC will host a Mental Health and Wellness Lecture Series to inform the public of new discoveries into the causes and treatments of mental health illnesses. The series is free and open to the public. Programs will be held at Carnegie Libraries throughout the area.

Leading Child Development Experts Will Gather In Los Angeles To Discuss Latest Research And Practice Issues On Early Childhood Development

Nearly 2,000 early childhood professionals from across the country will gather in Los Angeles in early December at Zero To Three's 23rd National Training Institute (NTI) to discuss how to best support the health and development of babies and toddlers. America's Pediatrician Dr. T. Berry Brazelton, a founder of Zero To Three, will open the conference as he shares his groundbreaking work in the field of infant development. The National Training Institute, held Dec.